IL13R alpha 2 CAR-T by TCR Cure Biopharma Technology for Glioma: Likelihood of Approval

IL13R alpha 2 CAR-T is under clinical development by TCR Cure Biopharma Technology and currently in Phase I for Glioma.

PENN Gaming PENN stock #shorts

August 15, 2023

Shareholders approve all agenda items – Biotech Investments

EQS-News: SCHOTT Pharma AG & Co. KGaA / Key word(s): AGM/EGM SCHOTT Pharma with successful Annual General Meeting: Shareholders approve all agenda items 04.02.2025 /

February 5, 2025

Maternal RSV Vaccine Appears Safe, Real-World Study Finds

Administration of the maternal respiratory syncytial virus prefusion F (RSVpreF) vaccine (Abrysvo) didn’t come with an increased risk of preterm birth or other negative neonatal

July 9, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.